Frontotemporal lobar degeneration is heterogeneous; cases with tau-and synuclein-negative, ubiquitin-positive neuronal inclusions are the most common, and some have mutations in the gene for progranulin (PGRN). The purpose of this study was to determine whether there were distinctive clinical and neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with PGRN mutations. A retrospective review of medical records and semiquantitative neuropathologic analysis was performed on 18 PGRN(+) and 24 PGRN(j) cases. Clinically, PGRN(+) cases had more frequent language impairment and parkinsonism. Pathologically, PGRN(+) cases had smaller brains, more marked global atrophy, and more frontal atrophy. There was no difference in the frequency of hippocampal sclerosis. The pathology of PGRN(+) cases was relatively homogeneous, whereas PGRN(j) cases were more heterogenous. PGRN(+) cases had greater density of cortical ubiquitin-immunoreactive lesions, especially dystrophic neurites in layer II. Intranuclear inclusions were present in all PGRN(+) and 42% of PGRN(j) cases. The results suggest that frontotemporal lobar degeneration with ubiquitinpositive inclusions due to PGRN mutations has several characteristic features, including ubiquitin-immunoreactive neuritic pathology in superficial cortical layers and neuronal intranuclear inclusions. On the other hand, there is no histopathologic feature or combination of features that is pathognomonic. Neuronal intranuclear inclusions are virtually always present, but they can be detected in PGRN(j) cases.
INTRODUCTION
Frontotemporal dementia is a clinical term applied to subjects who present with a progressive dementia characterized by prominent behavioral abnormalities, personality changes, executive dysfunction, and language impairment (1, 2) . The microscopic pathology of the frontotemporal lobar degenerations (FTLD) is diverse and includes cases with tau-immunoreactive neuronal and glial lesions (i.e. tauopathies), including Pick disease and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) as well as disorders that do not have tauimmunoreactive lesions (3Y6). The latter are a heterogeneous group of disorders with ubiquitin-immunoreactive, but tau-and synuclein-negative neuronal inclusions (FTLD-U), motor neuron disease, and other rare disorders with no distinctive histopathology or neuronal inclusions composed of neuronal intermediate filaments (7) .
Previous genetic studies of FTDP-17 identified mutations in the gene for the microtubule association protein tau (MAPT) in tauopathies (8) , but some tau-negative cases with the pathologic features of FTLD-U and no evidence of MAPT mutations were also shown to be linked to chromosome 17 (9) . Most of these cases had ubiquitin-immunoreactive neuronal inclusions (9) . Recently, mutations in the progranulin gene (PGRN) were detected in chromosome 17-linked FTLD-U (10, 11) . The mutations lead to truncated or no messenger RNA and no translation due to degradation of truncated mRNA species in a process referred to as nonsense-mediated decay (10) . The aim of this study was Copyright @ 2007 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
to compare clinical and pathologic features of FTLD-U in cases with and without PGRN mutations.
MATERIALS AND METHODS

Case Ascertainment
All cases of FTLD-U in the neuropathology files of the Mayo Clinic that had screened positive or negative for mutations in PGRN were retrieved for further study. The only inclusion criteria were that fixed tissue or paraffin blocks had to be available for additional histopathologic studies and the case had to have been previously screened for PGRN mutations as part of a larger study that analyzed more than 370 cases of frontal lobe dementia diagnosed either clinically or pathologically (12) . The only exception was inclusion of 2 individuals who were members of a kindred with PGRN mutations in whom the mutation was inferred based on genealogy.
The case material was derived from several sources, including the Mayo Clinic Alzheimer Disease Research Center [n = 16: PGRN(+), n = 9 and PGRN(j), n = 7], State of Florida Alzheimer Disease Initiative [n = 16: PGRN(+), n = 3 and PGRN(j), n = 13], Society for Progressive Supranuclear Palsy brain bank [n = 5: PGRN(+), n = 3 and PGRN(j), n = 2], Albert Einstein College of Medicine brain bank [n = 3: PGRN(+), n = 2 and PGRN(j), n = 1], and cases sent to Mayo Clinic Jacksonville for diagnostic consultation [n = 2: PGRN(+), n = 1 and PGRN(j), n = 1]. As such, the amount and depth of available clinical information were variable. Five cases were from 1 kindred (F142) and 2 were from another kindred (F129) (13); all were followed at the Mayo Clinic. The 18 PGRN(+) cases included 11 different PGRN mutations. The technique for screening of the PGRN gene mutations was described in detail in recent publications (10, 12) .
Pathologic Analyses
In all cases, slides of frontal, temporal, parietal, and occipital neocortex, as well as hippocampus, basal ganglia, thalamus, midbrain, pons, and medulla were reviewed. In some cases, spinal cord samples were available as well. In addition to routine histologic methods, including hematoxylin and eosin (H&E), thioflavin-S fluorescent microscopy, and Bielschowsky silver stains, all cases underwent immunohistochemical studies with a monoclonal antibody to ubiquitin (Ubi-1, 1:40,000; EnCor Biotechnology, Alachua, FL) and phospho-tau (either AT8, 1:1000 [Endogen, Woburn, MA] or CP13, 1:500 [from Peter Davies, Albert Einstein College of Medicine, New York, NY]). Cases with any degree of substantia nigra degeneration were screened with >-synuclein immunohistochemistry using previously described methods, including pretreatment of sections with 95% formic acid (rabbit polyclonal NACP; 1:5000 [14] or LB509; Zymed Invitrogen, Carlsbad, CA). All slides were reviewed for the presence of additional pathologic processes, including infarcts, Alzheimer-type pathology, and argyrophilic grains, and in a subset of cases, immunohistochemistry was performed with antibodies to phosphorylated neurofilament (SMI-31, monoclonal, mouse, 1:5000; Sternberger, Lutherville, MD) and >-internexin (1:1000 dilution; EnCor Biotechnology) to exclude neurofilament inclusion body disease (7, 15) . Mayo Clinic cases also had immunohistochemistry for A-amyloid (6F/3D, 1:10 dilution; Vector Laboratories, Burlingame, CA) and >-B crystallin (1:5000; Novocastra, Newcastle, UK). Select cases had immunohistochemistry for TAR DNA binding protein 43 (TDP-43) (1:8000; Proteintech Group, Chicago, IL).
Semiquantitative Analyses
Cortical and Striatal Degeneration H&E-stained slides from the frontal, temporal, and parietal cortices and the caudate nucleus were reviewed to determine the relative severity of neuronal loss, spongiosis, and gliosis. The analysis was conducted by an experienced neuropathologist (DWD) using scoring methods that were similar to those used in previously published studies (16Y19). For the purpose of this report inter-rater reliability of the semiquantitative analyses was not established.
For each region, cortical degeneration was graded on a 4-point semiquantitative scale. Briefly, 0 = no overt neuronal loss or gliosis, 1 = mild neuronal loss associated with microvacuolation of the superficial cortical layers, 2 = moderate neuronal loss and gliosis affecting all cortical layers and associated with thinning of the cortical layers, and 3 = endstage neuronal loss and gliosis associated with status spongiosis. The degree of striatal atrophy was assessed similarly on a 3-point grading scale: 0 = no neuronal loss or gliosis; 1 = mild flattening of the caudate with mild striatal neuronal loss and gliosis; and 2 = moderate-to-severe flattening of the caudate head with moderate-to-severe striatal neuronal loss and gliosis with spongiosis.
Presence of Intranuclear Inclusions
Sections of frontal and temporal neocortex, dentate granule cells of the hippocampus, and striatum that had been immunostained for ubiquitin were screened for the presence of neuronal intranuclear inclusions (NIIs). Cases were recorded as positive or negative, even if there were only rare NIIs.
Presence and Severity of Hippocampal Sclerosis
Hippocampal sclerosis, a common feature of FTLD-U (19) , and its presence and severity were assessed on H&E-stained sections with a 3-point semiquantitative scale: 0 = no neuronal loss affecting the subiculum or the pyramidal layer of Ammon_s horn (CA1); 1 = neuronal loss and gliosis limited to the subiculum; and 2 = neuronal loss and gliosis in the subiculum and CA1.
Presence and Severity of Substantia Nigral Degeneration
The presence of degeneration in the substantia nigra was determined on H&E-stained sections with a 3-point semiquantitative grading scale: 0 = no neuronal loss or gliosis with preservation of the neuromelanin-laden cells; 1 = mild neuronal loss with some pigmentary degeneration; and 2 = moderate-to-severe neuronal loss with gliosis and a paucity of pigment positive neurons.
Evidence of Motor Neuron Degeneration
Neuronal loss, gliosis, and the presence of Bunina bodies were assessed in the hypoglossal nucleus with H&E. If available, spinal cord sections were also reviewed. The presence of Lewy bodyYlike hyaline and skein-like inclusions were assessed on ubiquitin immunostains, and the corticospinal tract was assessed for wallerian degeneration as previously described with Luxol fast blue stains usually supplemented with immunostains for activated microglia (18) .
Presence and Severity of Ubiquitin-Positive Pathology
The presence and morphology of ubiquitin immunoreactive neuronal lesions were noted as described previously (16) . The severity of ubiquitin immunoreactive pathology was assessed semiquantitatively in the neocortex, dentate gyrus, and striatum with ubiquitin immunohistochemistry as follows: 0 = no inclusions or neurites; 1 = sparse inclusions or neurites; 2 = moderate density of inclusions or neurites; and 3 = high density of inclusions or neurites.
Neurofibrillary Tangle Distribution
Neurofibrillary tangle distribution was determined from thioflavin-SY or Bielschowsky-stained sections and summarized by the Braak neurofibrillary tangle stage (20) .
Statistical Analyses
Nonparametric statistics were used to conduct the analyses. The Mann-Whitney U test was used to compare ages at death and symptomatic disease duration between cases and controls. A chi-square test was used to compare gender differences and differences between the absence and presence of a positive family history between cases and controls. For these analyses, statistical significance was set at p G 0.05. The average brain weights, atrophy of striatum, frontal, temporal, and parietal cortices, overall atrophy score, density of ubiquitin-positive inclusions in the cortex, dentate granule cells of the hippocampus, and stratum, frequency of intranuclear inclusions, degree of hippocampal sclerosis, and Braak stage were compared between cases and controls using the Mann-Whitney U test. Comparisons were grouped as follows: 1) regional atrophy (atrophy of striatum or frontal, temporal, or parietal cortices, overall atrophy, and brain weights); 2) ubiquitin-immunoreactive inclusions (intranuclear inclusions, density of cortical, dentate granule cells, and striatal pathology); and 3) other pathologic features (Braak stage, hippocampal sclerosis, Lewy bodies, etc.), and for each group significance was adjusted using the Hochberg method for multiple comparisons (21) . Spearman rank order correlation analysis was used for univariate correlations of pathologic features. Statistical analyses were performed with JMP computer software (version 6.0; SAS Institute Inc., Cary, NC) or SigmaStat for Windows (Systat Software, Inc., Point Richmond, CA).
RESULTS
Demographics and Clinical Features
Demographics and clinical features of PGRN(+) and PGRN(j) cases are summarized in Table 1 , and more detailed information is provided on the PGRN(+) cases in Table 2 . There were no differences between PGRN(+) and PGRN(j) cases with respect to age of onset, symptomatic disease duration or male-to-female ratio. In 82% of the subjects there was a family history of neurodegenerative disease (i.e. dementia, motor neuron disease, or parkinsonism), whereas only 55% of PGRN(j) cases had a family history of neurodegenerative disease. The presenting features and evolving clinical syndromes of the PGRN(+) cases were variable and included an initial diagnosis of 1 of the frontotemporal dementia syndromes (2) in most (11 of 18) of the subjects, of which 8 of 11 had the behavioral variant. The majority of the PGRN(+) cases (82%) eventually had prominent language impairment, and many became mute, with some cases becoming mute very early in their disease course consistent with primary progressive aphasia (22, 23) . In 2 cases the initial diagnosis was Parkinson disease. In 1 an alternative diagnoses of dementia with Lewy bodies was later considered because of the onset of cognitive impairment and hallucinations. In the other corticobasal degeneration was diagnosed because of failure of levodopa treatment and development of cortical apraxia (13) . One case had an initial diagnosis of progressive supranuclear palsy. Parkinsonism was eventually a feature in many PGRN(+) cases (73%). In 1 kindred (F142), 3 individuals had been diagnosed with Alzheimer disease and another with an amnestic variant of mild cognitive impairment (24) . Psychiatric features and seizures were also found in a few cases.
Comparison of Clinical Features in PGRN(+) and PGRN(j) FTLD-U
The presence of the major clinical features of the frontotemporal dementia syndromesVbehavioral and language impairmentVas well as parkinsonism was assessed in PGRN(+) and PGRN(j) cases and controls on the basis of a review of available clinical records. In some cases (e.g. those followed in the Alzheimer's Disease Research Center), medical records were detailed and included quantitative indices and neuropsychology, whereas in others the records were limited to medical summaries. Therefore, for the purpose of statistical comparison, cases were scored as Byes[ or Bno[ with respect to these major clinical syndromes regardless of when it occurred in the disease course. If there was no mention of the particular feature, it was recorded as missing rather than negative. End-stage mutism was not included as a language variant. Parkinsonism was excluded if in the opinion of the clinician it was related to neuroleptic medication. Despite the limitations imposed by the heterogeneous nature of the referral sources, there appeared to be differences in the frequency of the clinical features in PGRN(+) and PGRN(j) cases. The presence of frontal behavioral syndrome was similar (75% versus 68%), but progressive language impairment was significantly more frequent in PGRN(+) cases (82% versus 23%). Although of marginal significance (p G 0.05), parkinsonism also tended to be more common in PGRN(+) than in PGRN(j) cases (73% versus 36%).
Pathologic Features Neurodegenerative Pathology
The brain weight of PGRN(+) cases was significantly less than that for PGRN(j) cases (mean weight: 902 versus 1030 g) Table 3 . The pattern of cortical degeneration was predominantly frontotemporal in most cases, with moderateto-severe frontal atrophy in 17 of 18 (94%) PGRN(+) and 8 of 24 (33%) PGRN(j) cases (Fig. 1) . Moderate-to-severe temporal degeneration was detected in 10 of 18 (55%) PGRN(+) and 13 of 24 (54%) PGRN(j) cases. Moderate-tomarked parietal degeneration was detected in 9 of 18 (50%) Brain weight is mean T SD; all others are medians (25th percentile, 75th percentile). Average cortical degeneration score was the calculated mean of frontal, temporal and parietal scores for each case.
*, Remained significant after adjustments for multiple comparisons. PGRN, progranulin gene; FTLD-U, frontotemporal lobar degeneration with ubiquitin-positive inclusions; n.s., not significant. PGRN(+) but in only 4 of 24 (17%) PGRN(j) cases. Parietal degeneration was never detected in isolation; it was always associated with degeneration in frontal or temporal lobes or both.
Severity of cortical degeneration was greater in the frontal lobe in PGRN(+) compared with PGRN(j) cases (p G 0.001). There was also a trend for parietal degeneration to be greater in PGRN(+) than in PGRN(j) cases, but there was no difference in severity of temporal degeneration. The average cortical degeneration score for the 3 cortical areas was greater in PGRN(+) than in PGRN(j) cases in keeping with lower brain weights in PGRN(+) cases.
Degeneration in the caudate nucleus and to a lesser extent in putamen was common in FTLD-U, being found in 94% of PGRN(+) and 75% of PGRN(j) cases. The severity of stratal degeneration did not differ between the 2 groups. Degeneration of the substantia nigra was also relatively common in FTLD-U. It was detected in 78% of PGRN(+) but in only 33% of PGRN(j) cases. The severity of substantia nigra degeneration tended to be greater in PGRN(+) cases, but this did not reach statistical significance.
Ubiquitin-Immunoreactive Inclusions
NIIs were detected in all PGRN(+) cases as well as in 10 of 24 (42%) PGRN(j) cases (Table 4) . These were mainly lentiform in morphology (Fig. 2) , although a few cases had round intranuclear inclusions. Cases with NIIs were twice as likely to have a family history of neurodegenerative disease as those without NIIs. NIIs were detected in 8 cases without a family history, including 4 with PGRN mutations and 4 without PGRN mutations.
All cases, by design, had ubiquitin-positive neuronal inclusions consistent with a diagnosis of FTLD-U. Those with PGRN mutations, however, had a higher density of ubiquitin-positive neuronal inclusions and neuritic lesions in neocortex (p G 0.001). Neuritic processes in PGRN(+) cases tended to be dense in layer II of the cortex, where spongiosis was also greatest (Fig. 2) . Neuritic pathology in PGRN(+) cases was rather uniform and characterized by short, narrow, and irregular or curvilinear processes (Fig. 1) . In contrast, neuritic pathology in PGRN(j) cases was more heterogeneous. Some cases had neuritic pathologies similar to those in PGRN(+) cases, whereas others had sparse, thicker, and shorter neurites that had a less obvious laminar distribution, with some being found in lower cortical layers. Neuronal cytoplasmic inclusions were more often spherical in PGRN(j) cases and more pleomorphic in PGRN(+) cases (Fig. 2) .
Although the frequency and severity of dentate fascia pathology were not different between PGRN(+) and PGRN(j) cases, the morphology of the neuronal cytoplasmic inclusions tended to be different. In PGRN(+) cases, the inclusions were more often irregular, poorly circumscribed granular lesions, whereas those in PGRN(j) cases more often were round, well-circumscribed Pick bodyYlike inclusions (16) (Fig. 2) .
The frequency and density of striatal ubiquitin immunoreactive neuronal inclusions, including neuronal cytoplasmic inclusions, NIIs, and neurites were not significantly different in PGRN(+) and PGRN(j) cases, although NIIs tended to be more frequent in PGRN(+) cases. The inclusions in both PGRN(+) and PGRN(j) cases were immunoreactive for TDP-43 (25) (Fig. 3) .
Other Pathology
Many of the cases had additional pathologic processes, such as Alzheimer-type changes, Lewy bodies, and vascular lesions (Table 5 ). There was no difference in the frequency of other pathologic features between PGRN(+) and PGRN(j) cases. The Braak neurofibrillary tangle stage did not differ. Hippocampal sclerosis was detected in 15 (83%) 
both frontal and temporal horns in (B). The hippocampus in (A) is relatively preserved, but severely affected in (B). Striatal atrophy is greater in (A) than in (B).
There is a small lacunar infarct in the caudate in (A). of PGRN(+) and 18 (75%) PGRN(j) cases. In 6 PGRN(+) and 10 PGRN(j) cases, neuronal loss was limited to the subiculum, whereas the other cases with hippocampal sclerosis had neuronal loss and gliosis affecting both the subiculum and CA1 region of the hippocampus. The severity of hippocampal degeneration did not differ between PGRN(+) and PGRN(j) cases.
Clinicopathologic Correlations
For all cases considered together, the presence of language impairment correlated with the severity of brain degeneration, particularly brain weight and degeneration in frontal and parietal lobes, as well as with the presence of cortical ubiquitin cytoplasmic inclusions and NIIs (Table 6) . Parkinsonism tended to correlate with the presence of substantia nigra degeneration but more significantly with NIIs. When considering only the PGRN(j) cases, similar trends were noted for language impairment and degeneration in cortical and subcortical areas. There were also trends for language impairment and cortical ubiquitin pathology. Parkinsonism tended to correlate with similar factors, as well as substantia nigra degeneration. No significant correlates were evident when only PGRN(+) cases were considered, probably due to the uniformity of this group.
DISCUSSION
In this study we identified differences in clinical and pathologic features between subjects with FTLD-U with and without mutations in the PGRN gene. We determined that no feature by itself was specific to the mutation. Of clinical importance was the identification of cases who presented with parkinsonism, rather than dementia or aphasia. In addition, not all PGRN(+) cases had a family history of neurodegenerative disease. This finding has implications for future clinicopathologic analyses and diagnoses.
Clinical Considerations
The majority of cases with a mutation in PGRN met clinical diagnostic criteria for frontotemporal dementia (2). These cases either had typical behavioral changes and executive dysfunction of the frontal variant of frontotemporal dementia or an aphasia syndrome (23) . Language impairment was more common in mutation carriers. Their clinical presentations, however, varied, and the initial clinical diagnoses varied. In those with prominent memory complaints, Alzheimer disease or an amnestic variant of mild cognitive impairment was the initial diagnosis. Parkinson disease and progressive supranuclear palsy were initial diagnoses in a few cases, and parkinsonism was eventually a feature in many cases. Parkinsonism tended to be more frequent in mutation carriers, but this did not reach statistical significance. Nevertheless, these initial findings suggest that it is important to exclude PGRN mutations in subjects with autosomal dominant parkinsonism.
The lack of family history of neurodegenerative disease in three PGRN(+) cases was probably due to incomplete clinical information in two cases. If nonpaternity 
Pathologic Considerations
All cases in this study by design had ubiquitinpositive inclusions in the frontotemporal neocortex, striatum, or dentate gyrus consistent with a pathologic diagnosis of FTLD-U (3, 26) . All cases lacked evidence of motor neuron disease, although previous reports suggested that some PGRN mutation carriers may have motor neuron disease (9) . It is likely that other genes are responsible for familial frontotemporal lobar degeneration with motor neuron disease (18) , with a candidate locus on chromosome 9 (27, 28) .
In addition to the findings of FTLD-U, there were other pathologies in a number of cases, including Lewy bodies, argyrophilic grains, senile plaques, neurofibrillary tangles, and infarcts. None of these features was significantly different in mutation carriers. One subject in this study had parkinsonism and clinical features suggestive of dementia with Lewy bodies (29) and autopsy evidence of diffuse cortical Lewy bodies. Another had clinical and pathologic evidence of Alzheimer disease. It was only after finding a PGRN mutation in either the subject or in a family member that the pathology was re-reviewed, specifically looking for ubiquitin-immunoreactive inclusions or neurites, and the diagnosis of FTLD-U was later confirmed. These 2 cases represent mixed dementiaVFTLD-U plus diffuse Lewy body disease and FTLD-U plus Alzheimer disease. The specificity of the diagnosis in these 2 cases was confirmed by immunohistochemistry with a recently reported specific marker for FTLD-U, TDP-43 (25) . This finding raises the question of whether ubiquitin (or TDP-43) immunohistochemistry should be performed on cortical and hippocampal sections in every subject with clinical features of frontotemporal dementia even if other pathologic processes are present on neuropathologic studies of the brain. Further studies are needed to address this pressing question.
The cases with FTLD-U with mutations in PGRN had significantly more ubiquitin-immunoreactive cortical pathology compared with those without mutations, but there were some PGRN(j) cases who had indistinguishable pathology. Another characteristic finding was the relative paucity of ubiquitin-immunoreactive inclusions in the dentate fascia, in which neuronal inclusions more often had a poorly circumscribed granular appearance. This morphology was noted previously in cases with motor neuron disease (16), but it was not until recently that the significance of these morphologic differences had a firm biologic basis. In particular, evidence suggests that TDP-43 is present in the inclusions of both motor neuron disease and FTLD-U (25) .
Attempts to differentiate histologic subtypes of FTLD-U have been reported (16, 30, 31) . The PGRN(+) cases in this series were most consistent with type 1 of Mackenzie et al (30) and possibly type 3 of Sampathu et al (31) , in that these types were associated with predominantly superficial cortical inclusions with neuritic pathology and intranuclear inclusions. Whether histologic subtypes of FTLD-U have interrater reliability and clinically meaningful predictive validity awaits a systematic multicenter study.
Recent reports have suggested that NIIs are specific to familial forms of FTLD with and without motor neuron disease (32Y34). Similarly, in the description of the pathologic features of FTLD-U associated with PGRN mutations, NIIs were hypothesized to be characteristic of familial disease (10) . On the other hand, NIIs are also detected in FTLD-U with no family history of neurodegenerative disease (16, 31, 35) and in cases without mutations in PGRN. In the present study, NIIs were found in 32 of 42 cases, including 3 individuals with PGRN mutations but no family history of neurodegenerative disease and 5 individuals with neither a PGRN mutation nor a family history of neurodegenerative disease ( Table 7 ). The presence of NIIs is not specific for PGRN mutations because other genetically determined forms of FTLD-U, e.g. FTLD-U, due to mutations in valosin-containing protein, also have been shown to have NIIs (36) . Hence, NIIs are a characteristic feature of FTLD-UYassociated with mutations in PGRN, but they are not specific.
The PGRN(+) cases had significantly more generalized atrophy and a smaller brain at autopsy than PGRN(j) cases. It is therefore possible that the mutation results in a more malignant form of FTLD. Analogously, greater severity of Alzheimer disease pathology is found in genetically determined familial Alzheimer disease (37) . The brunt of the atrophy in PGRN(+) cases was in the frontal lobe, although the parietal lobes also tended to be disproportionately affected, while temporal lobe degeneration was similar in mutation carriers and those without PGRN mutations.
The great majority of PGRN(+) cases (94%) had striatal degeneration with ubiquitin-positive neuronal inclusions, whereas striatal pathology was only slightly less frequent in PGRN(j) cases (75%). It is unclear whether this represents a difference in regional vulnerability of the striatum in FTLD-U due to PGRN mutations. Striatal pathology has been suggested to differentially define subsets of FTLD-U (16), but the present results raise the possibility that striatal pathology may be a function of overall disease severity, because there was a correlation between brain weight and striatal degeneration, just as there was a similar correlation between brain weight and severity of cortical degeneration.
Hippocampal sclerosis is increasingly recognized as a common feature of FTLD (38) , and in the present study it was common in cases with and without PGRN mutations. Its mere presence cannot help to differentiate familial from sporadic FTLD-U. Substantia nigra degeneration was common in the FTLD-U cases studied here, and it appeared to be more frequent in cases with PGRN mutations; however, because of the small sample size the frequency (78% versus 33%) and severity of nigral degeneration did not reach statistical significance (p = 0.09). Nevertheless, it is of interest that parkinsonism also tended to be more frequent in cases with PGRN mutations (73% versus 36%). Additional clinicopathologic studies are needed on a larger series of cases to determine the frequency of nigrostriatal degeneration and its consequent parkinsonism in PGRN(+) FTLD-U.
There are strengths and weaknesses of the present study. Among the strengths is the fact that this is one of the largest case-control clinicopathologic studies of PGRNrelated FTLD-U. Another strength of this study is that all cases underwent a similar in-depth neuropathologic evaluation, including application of immunohistochemistry and semiquantitative analysis of lesion density. A minor weakness is that the cohort of 18 cases had 11 different PGRN mutations. A large multicenter study, such as that reported for presenilin mutations (39), might be needed for genotypeY phenotype analysis. On the other hand, all reported mutations in PGRN have a similar functional effect, with degradation of truncated mRNA species in a process referred to as nonsense-mediated decay (10) . Thus, despite diversity in mutations, the net effect of each mutation is theoretically the same. Another weakness in this study and one that is inherent to many autopsy series is selection bias related to which individuals go to autopsy, with those with the more atypical disease often being preferentially autopsied (40) .
Although some of the cases in this series were part of prospective longitudinal studies, they were not all so studied and the cases, in fact, came from a variety of clinical and pathologic sources, including studies focusing on aging and dementia, as well as atypical parkinsonian disorders, such as progressive supranuclear palsy (41) . This inherently limits clinicopathologic correlations, particularly because the clinical data were not collected in a uniform manner. Despite these limitations, we have demonstrated a common constellation of neuropathologic features in FTLD-U due to mutations in PGRN and have suggested from clinicopathologic correlations a feature (nigrostriatal degeneration and parkinsonism) that should be systematically explored in future investigations of PGRN-related FTLD-U.
In this study we identified FTLD-U in some cases that initially carried alternative neuropathologic diagnoses and suggest that FTLD-U is easily missed in subjects with mixed pathologies. Routine application of immunohistochemistry for ubiquitin or, even better, for TDP-43 (25) , should be incorporated in diagnostic evaluation of neurodegenerative disorders, particularly when there is a family history or other features (e.g. hippocampal sclerosis) that might suggest FTLD-U, even when there are other common pathologic processes, such as Alzheimer-type pathology or Lewy bodies.
